Who we are
ALK is a global, research-driven pharmaceutical company that focuses on allergy prevention, diagnosis and treatment. The company specialises in allergy immunotherapy – which not only reduces allergic symptoms but also treats the underlying cause of a specific allergy.
ALK was founded in 1923 and, since then, has been working to improve quality of life for allergy patients whose disease continues to impact their lives in limiting ways.
What we do
At ALK, we recognise that living with uncontrolled allergy impacts everyday lifeat home, work and play. As a world leader within allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication. We are doing this by developing products that provide long-lasting relief.
ALK offers allergy immunotherapy products in the form of subcutaneous injections, sublingual drops and sublingual tablets.
In addition, ALK also produces an adrenaline auto-injector for the treatment of severe allergic reactions (anaphylaxis) and products used in the diagnosis of allergies.
As a treatment concept, allergy immunotherapy is now more than 100 years old. As a constant pioneer in the field, ALK has challenged and pushed the boundaries of allergy treatment. Today, allergy immunotherapy is entering a new era, with the advent of convenient tablet-based treatments, first introduced by ALK in 2006.
At the same time, ALK is reinvesting a large part of its annual revenue into the discovery and development of future medicines, while also raising awareness about new treatment options among healthcare professionals and patients alike.
Learn more on ALK at www.alk.net